Eli Lilly has announced its intention to acquire three vaccine developers—Curevo, LimmaTech Biologics, and Vaccine Company—in a move that could cost the pharmaceutical giant up to $4 billion. This acquisition is part of Lilly's broader strategy to enhance its portfolio in the biopharmaceutical sector, particularly in the development of vaccines targeting pathogens associated with long-term health issues. The company has been on an acquisition spree, leveraging its substantial cash reserves from its successful GLP-1 drug business, which has significantly boosted its financial standing.
The acquisitions come at a time when the demand for innovative vaccine solutions is high, especially in the wake of the COVID-19 pandemic, which has underscored the importance of rapid vaccine development and deployment. By investing in these early- and mid-stage companies, Lilly aims to position itself as a key player in the vaccine market, potentially addressing various infectious diseases and improving public health outcomes.
Healthcare professionals and stakeholders in the biopharma industry should monitor these developments closely, as they may lead to significant advancements in vaccine technology and availability. The integration of these companies into Lilly's operations could accelerate research and development timelines, ultimately benefiting patients and healthcare systems worldwide. As Lilly continues to expand its capabilities, the industry may see a shift in how vaccines are developed and distributed, paving the way for new therapeutic options in the future.
STAT News · 5d agoIn a recent examination of AbbVie’s patent practices surrounding its blockbuster drug Humira, it has been revealed that the company holds an astonishing 136 patents related to the medication. This extensive patent portfolio has allowed AbbVie to maintain a monopoly on Humira, delaying the entry of cheaper alternatives into the market until 2023. The original patent for Humira expired in 2016, yet AbbVie’s strategy of obtaining patents for various uses and formulations of the same molecule has extended its market exclusivity by an additional seven years. This has resulted in significant financial gains for the company, with projected revenues of $114 billion during this extended monopoly period, surpassing the earnings from the first 13 years post-FDA approval in 2002.
The Senate Committee on Finance, during a 2019 hearing, questioned AbbVie’s CEO Richard Gonzalez about the justification for such a large number of patents. Gonzalez argued that these patents represented legitimate innovations, as they pertained to different conditions treated by Humira. However, critics argue that this practice, often referred to as creating a 'patent thicket,' is a tactic used by pharmaceutical companies to stifle competition and maintain high drug prices. Humira's price has increased by 470% since its launch, now costing approximately $77,000 annually.
Further investigations by the House Committee on Oversight and Reform have uncovered documents indicating that AbbVie, with the assistance of consulting firm McKinsey, actively sought ways to block competition through strategic patenting and litigation. This included brainstorming sessions that generated over 200 ideas for new patents, incentivizing employees with rewards for patent submissions. The investigation highlights a broader concern regarding the pharmaceutical industry's practices in extending monopolies and the implications for drug pricing and accessibility.
As the landscape of drug pricing continues to evolve, the scrutiny of AbbVie’s practices raises important questions about the balance between innovation and market competition. The upcoming years will be critical as competitors prepare to enter the market, potentially reshaping the dynamics of pricing and availability for patients reliant on Humira and similar biologics.
STAT News · 5d agoIn light of recent public health emergencies, including an Ebola outbreak in the Democratic Republic of the Congo and Uganda, and a cluster of hantavirus cases linked to a Dutch cruise ship, eight former directors of the Centers for Disease Control and Prevention (CDC) have called for the reform of the President’s Emergency Plan for AIDS Relief (PEPFAR) rather than its dismantling. They emphasize the importance of PEPFAR, which has been instrumental in providing HIV treatment to over 8.1 million people and has saved more than 26 million lives since its inception in 2003. The program not only supports HIV treatment but also strengthens global health security through laboratory and disease-surveillance systems that protect Americans from outbreaks originating overseas.
The authors warn that a new State Department plan could jeopardize PEPFAR by freezing funds necessary for CDC cooperative agreements, potentially leading to the closure of 18 global CDC offices and a significant reduction in U.S. public health presence abroad. They argue that while the goal of transferring ownership of health programs to partner countries is valid, the current approach risks dismantling vital infrastructure before effective alternatives are established. This could result in a rapid decline of U.S. influence and capability in global health, echoing past experiences with the U.S. Agency for International Development (USAID).
To ensure a successful transition, the authors advocate for a well-defined, multiyear plan that preserves American technical capacity while fostering local ownership. They stress the need for collaboration between the State Department, CDC, and Congress to create a stable framework for reform that enhances both agencies and strengthens U.S. health security. Without careful planning, the authors warn that the consequences could be dire, leading to faster spread of outbreaks and increased threats to public health both domestically and globally.
STAT News · 5d ago